ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 305

Naming Is Everything! the Cost of Inappropriate “Lupus Panel” Testing

Caleb Anderson1, Roger Stitt 2 and Robert O'Brian 1, 1Walter Reed National Military Medical Center, Bethesda, MD, 2US Army, Ft Eustis

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anticardiolipin and systemic lupus erythematosus (SLE), Antiphospholipid antibodies, antiphospholipid syndrome, Health care cost

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Measures Of Healthcare Quality Poster I: Testing, Screening, & Treating

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Greater emphasis has been placed on cost saving measures due to ballooning healthcare cost in the U.S.  ACGME now evaluates trainee ability to practice cost conscious care through the systems based practice competency.  In the rheumatology clinic at Walter Reed National Military Medical Center (WRNMMC), we observed inappropriate ordering of the so called “lupus panel.”  The “lupus panel” lab is better known as the lupus anticoagulant test (LAC), which may be associated with the antiphospholipid syndrome (APS) and its clinical features of thromboembolic events and recurrent pregnancy loss.  We suspected the misleading name led physicians to order the “lupus panel” to screen for systemic lupus erythematosus (SLE) rather than to evaluate for APS.  We retroactively evaluated the rate and cost of inappropriate ordering of the “lupus panel” and found thousands of dollars spent annually on inappropriate ordering.  The lab name was changed from “lupus panel” to “lupus anticoagulation panel” based on our recommendation.  We then set out to evaluate a change in ordering pattern and resulting cost over a three month period.

Methods: Results of the “Lupus Panel” from 1 January 2015 – 31 December 2015 were collected.  The rationale for ordering each test was analyzed in the EMR by two rheumatologists.  The test was considered inappropriate if it was ordered for anything other than thrombophilia, initial SLE evaluation by a rheumatologist, or pregnancy loss.  The name of the lab was changed to “Lupus Anticoagulant Panel” on 1 April 2018. The ordering pattern from 1 April 2018 – 30 June 2018 was similarly evaluated. The lab processing cost, excluding labor, was estimated by our lab manager. Fisher’s exact test was utilized to evaluate the association between lab name and ordering pattern.

Results: 403 “lupus panel” lab tests were processed in the National Capital Region in 2015, at a rate of 33.6 per month. 148 (37%) samples were considered inappropriate, costing $4,722.68 ($393.56 per month) to process.  The three most common reasons for inappropriate testing were musculoskeletal complaints 63 (43%), fatigue 13 (8%), and paresthesias 6 (4%).  65 LAC tests were ordered in the first three months after the name change, at a rate of 22.3 per month. Of the 62 tests that had sufficient documentation to analyze, 14 were considered inappropriate (22.6%). The most common reasons for inappropriate testing were musculoskeletal complaints 6 (43%) and rash 5 (36%). The monthly cost of inappropriate lab tests was $147.79.

Conclusion: Inappropriate ordering of the “lupus panel” cost WRNMMC approximately $4,722.68 in lab processing for the calendar year 2015.  Changing the name of the lab to better describe the test yielded a significant reduction in the percentage of inappropriate lab tests (37% vs 22.6%, p=0.0318) and reduced annual and monthly cost by approximately $2,949.20 and $245.77, respectively.

Table One. Monthly cost of total and inappropriate lupus anticoagulant lab tests. Total monthly cost of “lupus panel” was $1072.18, with inappropriate lab tests costing $393.56. Total monthly cost of “lupus anticoagulant panel” was $711.60, with inappropriate lab tests costing $147.79.

Figure One: Reasons for inappropriate “lupus panel” testing

Figure Two: Reasons for inappropriate “lupus anticoagulant panel” testing


Disclosure: C. Anderson, None; R. Stitt, None; R. O'Brian, None.

To cite this abstract in AMA style:

Anderson C, Stitt R, O'Brian R. Naming Is Everything! the Cost of Inappropriate “Lupus Panel” Testing [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/naming-is-everything-the-cost-of-inappropriate-lupus-panel-testing/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/naming-is-everything-the-cost-of-inappropriate-lupus-panel-testing/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology